Recent submissions
Now showing items 101-120 of 456
-
Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry.
(NATURE PORTFOLIO, 2021-10-08)Mouse models are critical in pre-clinical studies of cancer therapy, allowing dissection of mechanisms through chemical and genetic manipulations that are not feasible in the clinical setting. In studies of the tumour ... -
PBAF loss leads to DNA damage-induced inflammatory signaling through defective G2/M checkpoint maintenance.
(COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT, 2022-07-28)The PBRM1 subunit of the PBAF (SWI/SNF) chromatin remodeling complex is mutated in ∼40% of clear cell renal cancers. PBRM1 loss has been implicated in responses to immunotherapy in renal cancer, but the mechanism is unclear. ... -
Defining Signatures of Arm-Wise Copy Number Change and Their Associated Drivers in Kidney Cancers.
(MDPI, 2019-11-16)Using pan-cancer data from The Cancer Genome Atlas (TCGA), we investigated how patterns in copy number alterations in cancer cells vary both by tissue type and as a function of genetic alteration. We find that patterns in ... -
Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis.
(AMER CHEMICAL SOC, 2016-10-13)Bromodomains (BRDs) are epigenetic interaction domains currently recognized as emerging drug targets for development of anticancer or anti-inflammatory agents. In this study, development of a selective ligand of the fifth ... -
Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan.
(Oxford University Press (OUP), 2016-10-26)The topoisomerase I (TOP1) inhibitor irinotecan triggers cell death by trapping TOP1 on DNA, generating cytotoxic protein-linked DNA breaks (PDBs). Despite its wide application in a variety of solid tumors, the mechanisms ... -
Cell cycle-dependent binding between Cyclin B1 and Cdk1 revealed by time-resolved fluorescence correlation spectroscopy.
(ROYAL SOC, 2022-06-29)Measuring the dynamics with which the regulatory complexes assemble and disassemble is a crucial barrier to our understanding of how the cell cycle is controlled that until now has been difficult to address. This considerable ... -
Investigating the role of DTX3L in the replication stress response
(Institute of Cancer Research (University Of London), 2023-01-20)DNA replication must be carried out with high fidelity to ensure accurate transfer of genetic information upon cell division. The mechanisms by which damage upon DNA is repaired are extensive and are increasingly well ... -
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
(ELSEVIER, 2022-05-01)OBJECTIVES: To assess health-related quality of life (HRQoL) with first-line pembrolizumab, pembrolizumab-chemotherapy, or cetuximab-chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) ... -
Characterisation of RELA dynamics in pancreatic ductal adenocarcinoma
(Institute of Cancer Research (University Of London), 2022-07-06)The NF-kB transcription factor RELA is a master regulator of the immune response and cell survival. Numerous studies have determined the parameters and configuration of single cell RELA translocation dynamics, with various ... -
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital.
(LIPPINCOTT WILLIAMS & WILKINS, 2022-05-01)PURPOSE: Patients with cancer are at increased risk of severe COVID-19 disease, but have heterogeneous presentations and outcomes. Decision-making tools for hospital admission, severity prediction, and increased monitoring ... -
COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE).
(ELSEVIER, 2022-05-08)BACKGROUND: ESMO COVID-19 and CAncer REgistry (ESMO-CoCARE) is an international collaborative registry-based, cohort study gathering real-world data from Europe, Asia/Oceania and Africa on the natural history, management ... -
OX40 and 4-1BB delineate distinct immune profiles in sarcoma.
(TAYLOR & FRANCIS INC, 2022-12-31)Systemic relapse after radiotherapy and surgery is the major cause of disease-related mortality in sarcoma patients. Combining radiotherapy and immunotherapy is under investigation as a means to improve response rates. ... -
Identification of phenotype-specific networks from paired gene expression-cell shape imaging data.
(COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT, 2022-04-01)The morphology of breast cancer cells is often used as an indicator of tumor severity and prognosis. Additionally, morphology can be used to identify more fine-grained, molecular developments within a cancer cell, such as ... -
Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
(NATURE PORTFOLIO, 2022-02-17)The development of covalent inhibitors against KRAS G12C represents a major milestone in treatment of RAS-driven cancers, especially in non-small cell lung cancer (NSCLC), where KRAS G12C is one of the most common oncogenic ... -
A ROS-dependent mechanism promotes CDK2 phosphorylation to drive progression through S phase.
(CELL PRESS, 2022-07-25)Reactive oxygen species (ROS) at the right concentration promote cell proliferation in cell culture, stem cells, and model organisms. However, the mystery of how ROS signaling is coordinated with cell cycle progression and ... -
Aneuploidy tolerance caused by BRG1 loss allows chromosome gains and recovery of fitness.
(NATURE PORTFOLIO, 2022-04-01)Aneuploidy results in decreased cellular fitness in many species and model systems. However, aneuploidy is commonly found in cancer cells and often correlates with aggressive growth, suggesting that the impact of aneuploidy ... -
Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.
(BMJ PUBLISHING GROUP, 2022-03-01)BACKGROUND: Despite therapeutic gains from immune checkpoint inhibitors (ICI) in many tumor types, new strategies are needed to extend treatment benefits, especially in patients failing to mount effective antitumor T-cell ... -
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.
(BMJ PUBLISHING GROUP, 2022-03-01)BACKGROUND: Combination herpes simplex virus (HSV) oncolytic virotherapy and BRAF inhibitors (BRAFi) represent promising immunogenic treatments for BRAF mutant melanoma, but an improved understanding of the immunobiology ... -
Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients.
(AMER ASSOC CANCER RESEARCH, 2022-06-03)Improving the chances of curing patients with cancer who have had surgery to remove metastatic sites of disease is a priority area for cancer research. Pexa-Vec (Pexastimogene Devacirepvec; JX-594, TG6006) is a principally ... -
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
(OXFORD UNIV PRESS, 2022-03-04)In the randomized, phase 3 CheckMate 141 trial, nivolumab significantly improved overall survival (OS) versus investigator's choice (IC) of chemotherapy at primary analysis among 361 patients with recurrent or metastatic ...